Chemokine receptor antagonists with α1-adrenergic receptor blocker activity.
Anthony J DeSantisGarrett A EntenXianlong GaoMatthias MajetschakPublished in: Journal of basic and clinical physiology and pharmacology (2021)
Our data suggest that CCR antagonists should be screened for cross-reactivity with α1-adrenoceptors to exclude potential adverse cardiovascular effects when used as anti inflammatory drugs.